+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Orphan Drug"

From
From
Drug Repurposing Market 2024-2028 - Product Thumbnail Image

Drug Repurposing Market 2024-2028

  • Report
  • October 2024
  • 198 Pages
  • Global
From
Orphan Drugs Market 2024-2028 - Product Thumbnail Image

Orphan Drugs Market 2024-2028

  • Report
  • August 2024
  • 180 Pages
  • Global
From
Nucleic Acid Drug Market in China - Product Thumbnail Image

Nucleic Acid Drug Market in China

  • Report
  • September 2025
  • 150 Pages
  • China
From
Nucleic Acid Drug Market in Canada - Product Thumbnail Image

Nucleic Acid Drug Market in Canada

  • Report
  • September 2025
  • 150 Pages
  • Canada
From
From
Pharmacovigilance Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Pharmacovigilance Market - Forecasts from 2024 to 2029

  • Report
  • April 2024
  • 123 Pages
  • Global
From
Rare Disease Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Rare Disease Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Pharmaceutical Review Designations: Trends and Industry Insights - Product Thumbnail Image

Pharmaceutical Review Designations: Trends and Industry Insights

  • Report
  • December 2024
  • 48 Pages
  • Global
From
Strategic Intelligence: Orphan Designated Drugs - Product Thumbnail Image

Strategic Intelligence: Orphan Designated Drugs

  • Report
  • August 2024
  • 54 Pages
  • Global
From
Rare Disease ?Pipeline Analysis ?Landscape in 2023 - Product Thumbnail Image

Rare Disease ?Pipeline Analysis ?Landscape in 2023

  • Drug Pipelines
  • February 2024
  • 29 Pages
  • Global
From
Loading Indicator

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them. The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives. Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more